Esophageal cancer is relatively uncommon. In the United States, the incidence rate is 4.2 per 100,000 people per year, making it far less frequent than cancers of the breast, lung, or colon. But its high fatality rate and sharp differences across sex, geography, and subtype make it worth understanding in detail.
U.S. Incidence and Death Rates
Based on cases from 2018 to 2022, about 4 out of every 100,000 Americans are diagnosed with esophageal cancer each year. The death rate is nearly as high: 3.7 per 100,000 per year. That narrow gap between diagnosis and death reflects the fact that esophageal cancer is often caught late and is difficult to treat at advanced stages.
Roughly 19,000 to 20,000 new cases are diagnosed in the U.S. each year. For context, that’s about one-fifteenth the number of new breast cancer diagnoses annually. Esophageal cancer accounts for about 1% of all cancers diagnosed in the country.
Who Gets It: Sex, Age, and Race
Men are diagnosed with esophageal cancer about four times as often as women, and they die from it at a similarly lopsided rate. In a typical year, roughly 15,000 of the 19,000 U.S. cases occur in men. This gap holds across both major subtypes of the disease, though it’s more extreme for one of them: men are 7 to 10 times more likely than women to develop adenocarcinoma of the esophagus, and 3 to 4 times more likely to develop squamous cell carcinoma.
No single risk factor fully explains this sex difference. Researchers have analyzed a wide range of variables and found that none of them strongly or uniquely accounts for why men are so much more affected. Higher rates of smoking and alcohol use in men play a role, but the disparity persists even after adjusting for known risk factors.
Most diagnoses occur in people over 55, and the disease is rare in younger adults. In the U.S., adenocarcinoma (the subtype linked to chronic acid reflux) is especially concentrated among white men, who accounted for 76% of adenocarcinoma cases between 1973 and 2012. Squamous cell carcinoma, the other major subtype, is more evenly distributed across racial groups but still disproportionately affects men.
Two Subtypes With Different Patterns
Esophageal cancer isn’t one disease. The two main subtypes, adenocarcinoma and squamous cell carcinoma, have different causes, affect different populations, and are trending in opposite directions.
Squamous cell carcinoma develops in the flat cells lining the upper and middle esophagus. It’s strongly linked to smoking and heavy alcohol use. Globally, it remains the more common form, especially in parts of Asia and Africa. In the U.S., though, its incidence has been falling for decades.
Adenocarcinoma develops in the lower esophagus, near the stomach, and is tied to chronic gastroesophageal reflux disease (GERD) and obesity. This subtype has been rising sharply. It surpassed squamous cell carcinoma around 1997 to become the dominant form in the U.S. From 1992 to 2019, adenocarcinoma incidence climbed by an average of 1.6% per year. Over that full period, the total increase was roughly 164%. Population aging and growth explain part of that rise, but changes in actual incidence (driven by rising obesity and reflux rates) account for the largest share, about 68% of the increase.
Meanwhile, overall esophageal cancer incidence in the U.S. has slowly declined, dropping an average of 0.7% per year, because the fall in squamous cell cases has more than offset the rise in adenocarcinoma.
Barrett’s Esophagus and Cancer Risk
One of the most common questions around esophageal cancer risk involves Barrett’s esophagus, a condition where chronic acid reflux changes the cells lining the lower esophagus. Barrett’s is considered a precursor to adenocarcinoma, but the actual risk of progression is low: approximately 0.33% per year, or about 1 in 300 people with Barrett’s developing cancer in any given year.
When you include both cancer and high-grade precancerous changes as a combined endpoint, the annual progression rate rises to roughly 0.9% to 1.0%. That means the vast majority of people with Barrett’s esophagus will never develop esophageal cancer, though regular monitoring with endoscopy is standard practice to catch changes early if they occur.
Geographic Differences Around the World
Esophageal cancer rates vary dramatically by region. The highest incidence areas form what researchers call the “Asian Esophageal Cancer Belt,” stretching from eastern Turkey through Iran, Central Asia (Kazakhstan, Turkmenistan, Uzbekistan, Tajikistan), and into Mongolia and western China. Parts of eastern and southern Africa also have very high rates.
In southern Africa, the age-adjusted rate in men reaches 22.3 per 100,000, more than five times the overall U.S. rate. Eastern Asia follows at 20.3 per 100,000 in men, and eastern Africa at 14.9 per 100,000. Europe and North America sit at the lower end of the global spectrum. These geographic differences are driven largely by squamous cell carcinoma and reflect regional patterns in diet, tobacco and alcohol use, and exposure to very hot beverages.
Survival Rates by Stage
Esophageal cancer’s reputation as a deadly disease is borne out by the numbers, but stage at diagnosis makes an enormous difference. Based on data from 2015 to 2021, the five-year relative survival rates from the American Cancer Society break down as follows:
- Localized (cancer confined to the esophagus): 49%
- Regional (spread to nearby lymph nodes or tissues): 28%
- Distant (spread to other organs): 5%
Nearly half of people diagnosed with localized disease are alive five years later, which is a meaningful improvement over historical survival figures. The challenge is that most cases aren’t caught at the localized stage. Esophageal cancer rarely causes noticeable symptoms (difficulty swallowing is the most common) until it has grown or spread, which is why the overall survival rate remains low. The close gap between the incidence rate (4.2 per 100,000) and the death rate (3.7 per 100,000) reflects how frequently this cancer is diagnosed at an advanced stage.